Latest Information Update: 10 Dec 2007
At a glance
- Originator FeRx
- Class Antineoplastics; Aziridines; Carbamates; Cytostatic antibiotics; Indoles; Small molecules
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 14 Jan 2004 Preclinical trials in Non-small cell lung cancer in USA (Intra-arterial)